FSMA Launches Next Phase of Drug Development Efforts for SMA
FSMA Release | November 11, 2010
Families of SMA (FSMA) announces Request for Proposals (RFP) for new drug programs to develop therapies for Spinal Muscular Atrophy. FSMA has made significant progress in advancing new therapies for SMA, starting with funding the first ever SMA drug program in 2000. The organization is now launching the next phase of therapeutic development work for SMA. FSMA is aiming to fund two new preclinical drug development programs in 2011, with more to follow. These multi-million dollar collaborations will focus on innovative methods of developing novel therapies for SMA, including both biologic and small molecule approaches. These programs will be multi-year in scope with a typical duration of three years. The requested proposals will be reviewed by the FSMA Translational Advisory Committee next spring.
SMAHeadlines.com 